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Dog ticks (also called wood ticks) are capable of spreading the agents 
of tularemia and Rocky Mountain spotted fever.
The adult stage of the female dog tick most frequently bites humans. 
The highest risk of being bitten by a dog tick occurs during the spring 
and summer.
The adult female dog tick has a dark brown body with whitish markings 
on its dorsal scutum (plate) located behind the mouthparts.
Unfed adult dog ticks are the size of a watermelon seed.
Deer ticks are capable of spreading the agents of Lyme disease, 
human granulocytic anaplasmosis/ehrlichiosis (HGA) and babesiosis.
The nymph and adult female stages of the deer tick most frequently bite 
humans.  The greatest risk of being bitten exists throughout the spring, 
summer and fall. However, deer tick adults may be out searching for a 
host any time winter temperatures are above freezing.
The adult female deer tick has a reddish-brown tear-drop shaped 
body with a dark brown dorsal scutum (plate) located behind the 
mouthparts.
Unfed deer tick nymphs are the size of a poppy seed and unfed adults 
are the size of a sesame seed.
Ticks are generally found in brushy or wooded areas, near the ground; they cannot jump or fly.  Ticks are attracted to a variety of host factors 






D E E R  T I C K IXODES SCAPULARIS A M E R I C A N  D O G  T I C K DERMACENTOR VARIABILIS













Algorithm for DifferentiAting tickborne DiseAses in mAssAchusetts
This algorithm is intended for use as a general guide when pursuing a diagnosis. It does not replace the physician’s clinical judgment or the 





Patient resides, works, or recreates in an area likely to have ticks and is exhibiting 
fever, headache, malaise and/or lymphadenopathy
Does the patient have a rash?
Yes No
Parasites in RBC*
Babesiosis             
*If patient has an international 
travel history, malaria should be 
ruled out
Morulae in WBC
Consider human granulocytic 
anaplasmosis/
ehrlichiosis, further tests may be 
indicated
Maculopapular
Consider human granulocytic 
anaplasmosis/ehrlichiosis, further 




Consider RMSF*, tularemia** or 
Lyme disease,
further tests may be indicated
* RMSF -- thrombocytopenia 
may occur














(ulceroglandular), further tests may 
be indicated
Maculopapular to Petechial*
Consider RMSF, further tests may 
be indicated
*If petechial rash of palms and 
soles (characteristic of RMSF) 
is present, treat immediately. 
Normal hematocrit, 
thrombocytopenia, leukopenia
Consider human granulocytic 
anaplasmosis/ehrlichiosis, further 
tests may be indicated







































lYme Disease AgentBACtERIA:  borrelia burgdorferi













































NOTE:  Coinfection with B. microti and/or A. phagocytophilum should be considered 
in patients who present with initial symptoms that are more severe than 
are commonly observed with Lyme disease alone, especially in those who 
have high-grade fever for more than 48 hours despite appropriate antibiotic 
therapy or who have unexplained leukopenia, thrombocytopenia, or anemia.  
Coinfection might also be considered in patients whose erythema migrans 
























eArly locAlizeD stAge 
AgE CATEgORy DRug DOSAgE MAxiMuM DuRATiON, DAyS (RANgE)
Adults Doxycycline 100	mg	twice	per	day N/A 14	(14-21)
Cefuroxime axetil 500	mg	twice	per	day N/A 14	(14-21)
Amoxicillin 500	mg	3	times	per	day N/A 14	(14-21)
Children Amoxicillin 50	mg/kg	per	day	in	3	divided	doses 500	mg	per	dose 14	(14-21)
Doxycycline 4	mg/kg	per	day	in	2	divided	doses 100	mg	per	dose 14	(14-21)
Cefuroxime axetil 30	mg/kg	per	day	in	2	divided	doses 500	mg	per	dose 14	(14-21)
NOTE: For patients intolerant of amoxicillin, doxycycline, and cefuroxime axetil,the macrolides azithromycin, clarithromycin, or erythromycin may be used, although they 
have a lower efficacy.  Patients treated with macrolides should be closely observed to ensure resolution of clinical manifestations.
Treatment guidelines for patients with disseminated or late stage Lyme disease are outlined in the reference below. †
Agent








































































•	 Identification	of	intraerythrocytic	Babesia parasites in a peripheral blood 
smear; or  
•	 Isolation	of	the	parasite	from	a	whole	blood	specimen	by	animal	inoculation;	or
•	 Positive	polymerase	chain	reaction	(PCR)	assay.
NOTE: Due to the sparse parasitemia typical of most Babesia microti infections, 
additional diagnostic tests should be performed in suspect patients if the 












































er Clindamycin 300-600	mg	IV	every	6	hours	OR	600	mg	orally	every	8	hours N/A 7-10


























er Clindamycin 7-10	mg/kg	IV	or	orally	every	6-8	hours 600	mg	per	dose 7-10
Quinine 8	mg/kg	orally	every	8	hours 650	mg	per	dose 7-10
NOTE: For adult patients who are immunocompromised, higher doses of azithromycin, 600-1000 mg per day, may be used.
NOTE: The recommended treatment for patients with severe babesiosis, as indicated by high-grade parasitemia (=> 10%), significant hemolysis, or renal, hepatic or 
pulmonary compromise, is quinine and IV clindamycin, and the patient should be considered for partial or complete RBC exchange transfusion.
NOTE: Consider the possibility of coinfection with B. burgdorferi and/or A. phagocytophilum in patients with especially severe or persistent symptoms, despite appropriate 
antibabesial therapy. 
NOTE: Asymptomatic patients with a positive babesial smear and/or PCR results should have these studies repeated. Treatment should be considered if parasitemia persists 

































































common finDings on routine lAborAtory tests 
















NOTE: Visualization of morulae in the cytoplasm of neutrophils or eosinophils during 
examination of blood smears is highly suggestive of a diagnosis; however, 
blood smear examination is insensitive and should never be relied upon 
solely to rule HGA in or out. 
NOTE: Confirmation of the diagnosis is based on laboratory testing, but antibiotic 
therapy should not be delayed in a patient with a suggestive clinical 
presentation.









AgE CATEgoRy DRug DoSAgE mAxImum DuRATIon (DAyS)





























Amoxicillin 50	mg/kg	per	day	in	3	divided	doses 500	mg	per	dose to	complete	a	14	day	total	course	of	
antibiotic therapy
OR
Cefuroxime axetil 30	mg/kg	per	day	in	2	divided	doses 500	mg	per	dose to	complete	a	14	day	total	course	of	
antibiotic therapy
NOTE: Patients with mild illness for whom doxycycline treatment is contraindicated may be treated with rifampin for 7-10 days using a dosage regimen of 300 mg twice per 
day by mouth for adults and 10 mg/kg twice per day for children (maximum, 300 mg per dose).
NOTE: Because HGA can be life-threatening and limited courses of therapy do not pose a substantial risk for tooth staining, the American Academy of Pediatrics has 
identified doxycycline as the drug of choice for treating HGA in children of any age.
NOTE: Treatment response is expected within 48 hours.











































[AverAge incubAtion perioD 3-5 DAys, rAnge 1-21 DAys]
NOTE: The clinical presentation of tularemia will depend on a number of factors, 
including the portal of entry.





























NOTE: Pneumonic tularemia should be considered in any patient presenting with 
community-acquired pneumonia who resides on, or has recently visited, 
Martha’s Vineyard.
Agent




























NOTE: Detection of organism by immunofluorescence assay (IFA) test or a single 
elevated serum antibody titer is supportive of the diagnosis; however, these 













Streptomycin 1	g	IM	twice	daily	 N/A 10	
Children Gentamicin 2.5	mg/kg	IM	or	IV	3	times	daily Consult a pediatric infectious disease specialist 10
OR
Streptomycin 15	mg/kg	IM	twice	daily 2	g/day 10
NOTE: Doses of both streptomycin and gentamicin need to be adjusted for renal insufficiency.
NOTE: Chloramphenicol may be added to streptomycin to treat meningitis.
NOTE: Alternative therapies to the preferred regimens of streptomycin and gentamicin are outlined in the reference below. †
Agent


































rockY mounTain spoTTeD fever
















or sudden transient deafness 
NOTE: Rash may be completely absent or atypical in up to 20% of RMSF cases.  
Rocky Mountain “spotless” fever is more likely to occur in older patients.
Agent

























immunofluorescence assay (IFA) test in paired sera; or
•	 Detection	of	DNA	in	a	clinical	specimen	by	polymerase	chain	reaction	(PCR)	




NOTE: Tests for IgM antibodies are generally not useful for serodiagnosis of acute 
disease, due to cross-reactivity and persistence of the antibody.
NOTE: Confirmation of the diagnosis is based on laboratory testing, but antibiotic 








AgE CATEgoRy DRug DoSAgE mAxImum DuRATIon (DAyS)
Adults Doxycycline 100	mg	twice	daily,	orally	or	IV N/A At	 least	 3	 days	 after	 the	 fever	 subsides	 and	 until	 evidence	 of	




Doxycycline 100	mg	twice	daily,	orally	or	IV Consult a pediatric infectious 
disease specialist
At	 least	 3	 days	 after	 the	 fever	 subsides	 and	 until	 evidence	 of	






Consult a pediatric infectious 
disease specialist
At	 least	 3	 days	 after	 the	 fever	 subsides	 and	 until	 evidence	 of	
clinical improvement is noted which is typically for a minimum 
total	course	of	5-7	days.
NOTE: Because RMSF can be life-threatening and limited courses of therapy do not pose a substantial risk for tooth staining, the American Academy of Pediatrics has 
identified doxycycline as the drug of choice for treating RMSF in children of any age.
































foR moRe infoRmation on tickboRne diseases:




Centers for Disease Control and Prevention
www.cdc.gov
American College of Physicians/American Society of internal Medicine 
http://www.acponline.org/lyme/ 
to RepoRt a case of tickboRne disease oR obtain infoRmation on the numbeR of 
cases of tickboRne diseases in youR aRea:
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